De Novo Sirolimus and Reduced-Dose Tacrolimus Versus Standard-Dose Tacrolimus After Liver Transplantation: The 2000–2003 Phase II Prospective Randomized Trial
Open Access
- 23 January 2014
- journal article
- research article
- Published by Elsevier BV in American Journal of Transplantation
- Vol. 14 (2), 356-366
- https://doi.org/10.1111/ajt.12543
Abstract
No abstract availableKeywords
Funding Information
- Wyeth
This publication has 30 references indexed in Scilit:
- Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled TrialAmerican Journal of Transplantation, 2012
- Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: An analysis of the Scientific Registry of Transplant Recipients DatabaseLiver Transplantation, 2012
- Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF—Four-Year Results of the Postconcept StudyAmerican Journal of Transplantation, 2011
- Reduced-Dose Tacrolimus with Mycophenolate Mofetil vs. Standard-Dose Tacrolimus in Liver Transplantation: A Randomized StudyAmerican Journal of Transplantation, 2011
- Management of hepatocellular carcinoma: An updateHepatology, 2011
- A Decade of Experience Using mTor Inhibitors in Liver TransplantationJournal of Transplantation, 2011
- Use of sirolimus in liver transplant recipients with renal insufficiency: A systematic review and meta-analysisHepatology, 2010
- Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipientsTransplant International, 2010
- Everolimus and mTOR inhibitors in liver transplantation: Opening the “box”Liver Transplantation, 2006
- Chronic Renal Failure after Transplantation of a Nonrenal OrganThe New England Journal of Medicine, 2003